303 related articles for article (PubMed ID: 26908330)
1. Circulating biomarkers and outcome from a randomised phase II trial of sunitinib vs everolimus for patients with metastatic renal cell carcinoma.
Voss MH; Chen D; Marker M; Hakimi AA; Lee CH; Hsieh JJ; Knox JJ; Voi M; Motzer RJ
Br J Cancer; 2016 Mar; 114(6):642-9. PubMed ID: 26908330
[TBL] [Abstract][Full Text] [Related]
2. Plasma cytokine and angiogenic factors associated with prognosis and therapeutic response to sunitinib vs everolimus in advanced non-clear cell renal cell carcinoma.
Msaouel P; Zurita AJ; Huang S; Jonasch E; Tannir NM
Oncotarget; 2017 Jun; 8(26):42149-42158. PubMed ID: 28178674
[TBL] [Abstract][Full Text] [Related]
3. Genomic Biomarkers of a Randomized Trial Comparing First-line Everolimus and Sunitinib in Patients with Metastatic Renal Cell Carcinoma.
Hsieh JJ; Chen D; Wang PI; Marker M; Redzematovic A; Chen YB; Selcuklu SD; Weinhold N; Bouvier N; Huberman KH; Bhanot U; Chevinsky MS; Patel P; Pinciroli P; Won HH; You D; Viale A; Lee W; Hakimi AA; Berger MF; Socci ND; Cheng EH; Knox J; Voss MH; Voi M; Motzer RJ
Eur Urol; 2017 Mar; 71(3):405-414. PubMed ID: 27751729
[TBL] [Abstract][Full Text] [Related]
4. Everolimus Versus Sunitinib Prospective Evaluation in Metastatic Non-Clear Cell Renal Cell Carcinoma (ESPN): A Randomized Multicenter Phase 2 Trial.
Tannir NM; Jonasch E; Albiges L; Altinmakas E; Ng CS; Matin SF; Wang X; Qiao W; Dubauskas Lim Z; Tamboli P; Rao P; Sircar K; Karam JA; McDermott DF; Wood CG; Choueiri TK
Eur Urol; 2016 May; 69(5):866-74. PubMed ID: 26626617
[TBL] [Abstract][Full Text] [Related]
5. Correlative serum biomarker analyses in the phase 2 trial of lenvatinib-plus-everolimus in patients with metastatic renal cell carcinoma.
Lee CH; Motzer RJ; Glen H; Michaelson MD; Larkin J; Minoshima Y; Kanekiyo M; Ikezawa H; Sachdev P; Dutcus CE; Funahashi Y; Voss MH
Br J Cancer; 2021 Jan; 124(1):237-246. PubMed ID: 33024271
[TBL] [Abstract][Full Text] [Related]
6. Significance of circulating matrix metalloproteinase-9 to tissue inhibitor of metalloproteinases-2 ratio as a predictor of disease progression in patients with metastatic renal cell carcinoma receiving sunitinib.
Miyake H; Nishikawa M; Tei H; Furukawa J; Harada K; Fujisawa M
Urol Oncol; 2014 Jul; 32(5):584-8. PubMed ID: 24680659
[TBL] [Abstract][Full Text] [Related]
7. Circulating proteins as potential biomarkers of sunitinib and interferon-α efficacy in treatment-naïve patients with metastatic renal cell carcinoma.
Harmon CS; DePrimo SE; Figlin RA; Hudes GR; Hutson TE; Michaelson MD; Négrier S; Kim ST; Huang X; Williams JA; Eisen T; Motzer RJ
Cancer Chemother Pharmacol; 2014 Jan; 73(1):151-61. PubMed ID: 24220935
[TBL] [Abstract][Full Text] [Related]
8. Phase II study of pazopanib as second-line treatment after sunitinib in patients with metastatic renal cell carcinoma: a Southern China Urology Cancer Consortium Trial.
Xie M; He CS; Huang JK; Lin QZ
Eur J Cancer; 2015 Mar; 51(5):595-603. PubMed ID: 25618828
[TBL] [Abstract][Full Text] [Related]
9. Phase II trial of second-line everolimus in patients with metastatic renal cell carcinoma (RECORD-4).
Motzer RJ; Alyasova A; Ye D; Karpenko A; Li H; Alekseev B; Xie L; Kurteva G; Kowalyszyn R; Karyakin O; Neron Y; Cosgriff T; Collins L; Brechenmacher T; Lin C; Morgan L; Yang L
Ann Oncol; 2016 Mar; 27(3):441-8. PubMed ID: 26681676
[TBL] [Abstract][Full Text] [Related]
10. Sunitinib-induced hypertension, neutropaenia and thrombocytopaenia as predictors of good prognosis in patients with metastatic renal cell carcinoma.
Rautiola J; Donskov F; Peltola K; Joensuu H; Bono P
BJU Int; 2016 Jan; 117(1):110-7. PubMed ID: 25252180
[TBL] [Abstract][Full Text] [Related]
11. Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins.
Deprimo SE; Bello CL; Smeraglia J; Baum CM; Spinella D; Rini BI; Michaelson MD; Motzer RJ
J Transl Med; 2007 Jul; 5():32. PubMed ID: 17605814
[TBL] [Abstract][Full Text] [Related]
12. Predictive value of C-reactive protein in patients treated with sunitinib for metastatic clear cell renal cell carcinoma.
Pilskog M; Beisland C; Akslen LA; Bostad L; Haug Å; Heinrich D; Hjelle KM; Straume O
BMC Urol; 2017 Aug; 17(1):74. PubMed ID: 28859644
[TBL] [Abstract][Full Text] [Related]
13. Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma.
Powles T; Choueiri TK; Motzer RJ; Jonasch E; Pal S; Tannir NM; Signoretti S; Kaldate R; Scheffold C; Wang E; Aftab DT; Escudier B; George DJ
BMC Cancer; 2021 Aug; 21(1):904. PubMed ID: 34364385
[TBL] [Abstract][Full Text] [Related]
14. An adjusted indirect comparison of everolimus and sorafenib therapy in sunitinib-refractory metastatic renal cell carcinoma patients using repeated matched samples.
Di Lorenzo G; Casciano R; Malangone E; Buonerba C; Sherman S; Willet J; Wang X; Liu Z; De Placido S
Expert Opin Pharmacother; 2011 Jul; 12(10):1491-7. PubMed ID: 21599551
[TBL] [Abstract][Full Text] [Related]
15. C-reactive protein as a prognostic marker for advanced renal cell carcinoma treated with sunitinib.
Fujita T; Iwamura M; Ishii D; Tabata K; Matsumoto K; Yoshida K; Baba S
Int J Urol; 2012 Oct; 19(10):908-13. PubMed ID: 22671963
[TBL] [Abstract][Full Text] [Related]
16. Second-line treatment outcomes after first-line sunitinib therapy in metastatic renal cell carcinoma.
Chen CC; Hess GP; Liu Z; Gesme DH; Agarwala SS; Garay CC; Hill JW; Guo A
Clin Genitourin Cancer; 2012 Dec; 10(4):256-61. PubMed ID: 22682982
[TBL] [Abstract][Full Text] [Related]
17. CXCL7 is a predictive marker of sunitinib efficacy in clear cell renal cell carcinomas.
Dufies M; Giuliano S; Viotti J; Borchiellini D; Cooley LS; Ambrosetti D; Guyot M; Ndiaye PD; Parola J; Claren A; Schiappa R; Gal J; Frangeul A; Jacquel A; Cassuto O; Grépin R; Auberger P; Bikfalvi A; Milano G; Escudier B; Rioux-Leclercq N; Porta C; Negrier S; Chamorey E; Ferrero JM; Pagès G
Br J Cancer; 2017 Sep; 117(7):947-953. PubMed ID: 28850564
[TBL] [Abstract][Full Text] [Related]
18. Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma.
Rini BI; Michaelson MD; Rosenberg JE; Bukowski RM; Sosman JA; Stadler WM; Hutson TE; Margolin K; Harmon CS; DePrimo SE; Kim ST; Chen I; George DJ
J Clin Oncol; 2008 Aug; 26(22):3743-8. PubMed ID: 18669461
[TBL] [Abstract][Full Text] [Related]
19. The Surge in the Number of Circulating Tumor Cells Following Treatment with Sunitinib for Metastatic Renal Cell Carcinoma.
Nagaya N; Kanayama M; Nagata M; Horie S
Intern Med; 2018 Sep; 57(18):2695-2700. PubMed ID: 29709937
[TBL] [Abstract][Full Text] [Related]
20. Are tyrosine kinase inhibitors still active in patients with metastatic renal cell carcinoma previously treated with a tyrosine kinase inhibitor and everolimus? Experience of 36 patients treated in France in the RECORD-1 Trial.
Blesius A; Beuselinck B; Chevreau C; Ravaud A; Rolland F; Oudard S; Escudier B
Clin Genitourin Cancer; 2013 Jun; 11(2):128-33. PubMed ID: 23332872
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
